Publications

Prognostic value of secretoneurin in chronic heart failure. Data from the GISSI-Heart Failure trial.
Helge Røsjø, Jennifer Meessen, Anett Hellebø Ottesen, Roberto Latini, Torbjørn Omland, on behalf of the GISSI-HF Investigators
Clinical Biochemistry 118 (2023)
https://doi.org/10.1016/j.clinbiochem.2023.110595

Circulating secretoneurin concentrations provide independent prognostic information to established risk indices in patients with chronic heart failure.
H. Rosjo, J. Meessen, A.H. Ottesen, R. Latini, T. Omland, on behalf of GISSI-HF Study
European Heart Journal, Volume 43, Issue Supplement_2, October 2022

Secretoneurin as a Novel Biomarker of Cardiovascular Episodes. Are We There Yet. A Narrative Review.

Plášek et.al, J. Clin. Med. 2022, 11(23), 7191

Biological variation of secretoneurin; a novel cardiovascular biomarker implicated in arrhythmogenesis.
Kristin M. Aakre, Anett H. Ottesen, Heidi Strand, Arne L. Faaren, Bashir Alaour, Janniche Torsvik, Marit S. Sylte, Michael Marber, Geir Christensen, Helge Røsjø, Torbjørn Omland
Clin Biochem 2021 Dec;98:74-77

Performance of a Novel Research-Use-Only Secretoneurin ELISA in Patients with Suspected Acute Coronary Syndrome: Comparison with an Established Secretoneurin Radioimmunoassay

Myhre et.al, Cardiology 2021;146:566–574

Circulating secretoneurin concentrations are increased in patients with acute coronary syndrome and provide prognostic information.
P. Myhre, A.H. Ottesen, A.L. Faaren, S.H. Tveit, J. Springett, J. Pyylampi, M. Stridsberg, G. Christensen, T. Omland, H. Rosjo
European Heart Journal, Volume 41, Issue Supplement_2, November 2020

 

Secretoneurin Is an Endogenous Calcium/Calmodulin-Dependent Protein Kinase II Inhibitor That Attenuates Ca2+-Dependent Arrhythmia
Anett H. Ottesen et.al, Circulation: Arrhythmia and Electrophysiology. 2019;12:e007045

 

Circulating secretoneurin concentrations in patients with moderate to severe aortic stenosis
Jon Brynildsen, Peder L. Myhre, Magnus N. Lyngbakken, Lars Gunnar Klaeboe, Mats Stridsberg, Geir Christensen, Thor Edvardsen, Torbjørn Omland, Helge Røsjø
Clin Biochem. 2019 Sep;71:17-23
Circulating Secretoneurin Concentrations After Cardiac Surgery: Data From the FINNish Acute Kidney Injury Heart Study
Jon Brynildsen, Liisa Petäjä, Peder L. Myhre, Magnus N. Lyngbakken, Ståle Nygård, Mats Stridsberg, Geir Christensen, Anett H. Ottesen, Ville Pettilä, Torbjørn Omland, Helge Røsjø
Crit Care Med. 2019 May;47(5):e412-e419

Albumin Italian Outcome Sepsis Study. Crit Care Med 2018 May;46(5):e404-e410
Røsjø et.al, Secretoneurin provides early and potent prognostic information in septic patients with cardiovascular instability. 

Prognostic Value of Secretoneurin in Patients With Severe Sepsis and Septic Shock: Data From the Albumin Italian Outcome Sepsis Study.

Røsjø H, Masson S, Caironi P, Stridsberg M, Magnoli M, Christensen G, Moise G, Urbano MC, Gattinoni L, Pesenti A, Latini R, Omland T; ALBIOS Biomarkers Study Investigators. Crit Care Med. 2018 May;46(5) 

Prognostic Value of Secretoneurin in Patients with Acute Respiratory Failure: Data from the FINNALI Study.

Myhre PL, Ottesen AH, Okkonen M, Linko R, Stridsberg M, Nygård S, Christensen G, Pettilä V, Omland T, Røsjø H; FINNALI Laboratory Study Group. Clin Chem. 2016 Oct;62(10):1380-9.

Prognostic Value of Secretoneurin in Critically Ill Patients with Infections.

Røsjø H, Stridsberg M, Ottesen AH, Nygård S, Christensen G, Pettilä V, Linko R, Karlsson S, Varpula T, Ruokonen E, Omland T; FINNSEPSIS and FINNALI Study Groups.

Crit Care Med. 2016 Oct;44(10):1882-90.

Secretoneurin is a novel prognostic cardiovascular biomarker associated with cardiomyocyte calcium handling.

Ottesen AH, Louch WE, Carlson CR, Landsverk OJ, Kurola J, Johansen RF, Moe MK, Aronsen JM, Høiseth AD, Jarstadmarken H, Nygård S, Bjørås M, Sjaastad I, Pettilä V, Stridsberg M, Omland T, Christensen G, Røsjø H.

J Am Coll Cardiol. 2015 Feb 3;65(4):339-51.

Will secretoneurin be the next big thing? 

Anderson ME. J Am Coll Cardiol. 2015 Feb 3;65(4):352-4.

Secretogranin II; a protein increased in the myocardium and circulation in heart failure with cardioprotective properties.

Røsjø H, Stridsberg M, Florholmen G, Stensløkken KO, Ottesen AH, Sjaastad I, Husberg C, Dahl MB, Øie E, Louch WE, Omland T, Christensen G.

PLoS One. 2012;7(5): e37401. Epub 2012 May 24.